Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Go back to Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer| NOVEN PHARMACEUTIC (NASDAQ: NOVN) | Delayed: 0.09 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.09 | 52 Week High | $23.79 | |||
| Open | $0.09 | 52 Week Low | $13.73 | |||
| Day High | $0.09 | P/E | 0.09 | |||
| Day Low | $0.09 | EPS | $1.05 | |||
| Volume | 765,077 | |||||
| NOVARTIS AG (NYSE: NVS) | Delayed: 99.16 +0.81 (0.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $98.35 | 52 Week High | $89.15 | |||
| Open | $98.63 | 52 Week Low | $69.84 | |||
| Day High | $99.21 | P/E | N/A | |||
| Day Low | $98.26 | EPS | $0.00 | |||
| Volume | 1,786,851 | |||||
